Gossamer Bio Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2023 | 225,409,315 | $23 | $1,275,136 | $(1,212,040) | $(350) | $62,769 |
| Stock-based compensation | — | — | 5,811 | — | — | 5,811 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 390,246 | — | 348 | — | — | 348 |
| Issuance of common stock for restricted stock units vested | 419,092 | — | — | — | — | — |
| Net loss | — | — | — | (41,928) | — | (41,928) |
| Other comprehensive loss | — | — | — | — | (278) | (278) |
| Balance as of March 31, 2024 | 226,218,653 | $23 | $1,281,295 | $(1,253,968) | $(628) | $26,722 |
| Stock-based compensation | — | — | 5,001 | — | — | 5,001 |
| Issuance of common stock for restricted stock units vested | 8,606 | — | — | — | — | — |
| Grant of equity option pursuant to Chiesi Collaboration Agreement | — | — | 464 | — | — | 464 |
| Net income | — | — | — | 49,232 | — | 49,232 |
| Other comprehensive income | — | — | — | — | 110 | 110 |
| Balance as of June 30, 2024 | 226,227,259 | $23 | $1,286,760 | $(1,204,736) | $(518) | $81,529 |
| Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive loss · Total stockholders' equity (deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 94,423,181 | $10 | $1,044,864 | $(1,032,223) | $(574) | $12,077 |
| Vesting of restricted stock | 55,225 | — | — | — | — | — |
| Stock-based compensation | — | — | 8,127 | — | — | 8,127 |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 249,623 | — | 367 | — | — | 367 |
| Issuance of common stock for restricted stock units vested | 716,067 | — | — | — | — | — |
| Net loss | — | — | — | (49,165) | — | (49,165) |
| Other comprehensive income | — | — | — | — | 138 | 138 |
| Balance as of March 31, 2023 | 95,444,096 | $10 | $1,053,358 | $(1,081,388) | $(436) | $(28,456) |
| Stock-based compensation | — | — | 8,197 | — | — | 8,197 |
| Issuance of common stock for restricted stock units vested | 8,607 | — | — | — | — | — |
| Net loss | — | — | — | (42,496) | — | (42,496) |
| Other comprehensive loss | — | — | — | — | (45) | (45) |
| Balance as of June 30, 2023 | 95,452,703 | $10 | $1,061,555 | $(1,123,884) | $(481) | $(62,800) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.